Shares of Advaxis plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated their collaboration on an immuno-oncology program.
Shares of Johnson & Johnson tumbled 12 percent after Reuters reported that the pharma major knew for decades that cancer-causing asbestos lurked in the company’s Baby Powder.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
The long-awaited and massively hyped initial public offering (IPO) of Moderna Therapeutics hit the market.
2018 was the year of the consumer, and there is no sign of a change any time soon.
The FDA issued draft guidance for biopharma companies on developing therapies for NASH with liver fibrosis.
Medtronic will pay a total of nearly $51 million to resolve three legal claims against Covidien Plc and ev3 Inc., two companies that are now part of the Ireland-based medtech company. Medtronic itself had no role in the wrongdoings that resulted in the multi-million fines.
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.